Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 4/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28751502 | 0.97 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPSR1MAPT | |
| SCHEMBL6030068 | 0.92 | HSD17B10 (0.48) | HSD17B10PLK1PLK3PPARGPPARA | |
| SCHEMBL6029893 | 0.92 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1NPSR1MAPT | |
| SCHEMBL6030216 | 0.90 | GAA (0.48) | HSD17B10SMN1; SMN2ALDH1A1NPSR1MAPT | |
| SCHEMBL6030384 | 0.90 | GAA (0.45) | HSD17B10SMN1; SMN2ALDH1A1NPSR1MAPT | |
| SCHEMBL6030363 | 0.89 | NPC1 (0.51) | HSD17B10SMN1; SMN2ALDH1A1PLK1PLK3 | |
| SCHEMBL6031150 | 0.89 | GAA (0.50) | HSD17B10SMN1; SMN2PLK1PLK3GLS | |
| SCHEMBL6030057 | 0.89 | GAA (0.50) | HSD17B10SMN1; SMN2PLK1PLK3GLS | |
| SCHEMBL6029701 | 0.89 | GAA (0.50) | HSD17B10SMN1; SMN2PLK1PLK3GLS | |
| SCHEMBL6031643 | 0.88 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064122-B2 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1467978-A4 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-11-02 | — | — | EP | disclosed |
| CN-1620439-A | Pancreatic lipase inhibitor compound, and synthesis method and application thereof | OSI PHARM INC (US) | 2005-05-25 | — | — | CN | disclosed |
| EP-1467978-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003053944-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | PNLIP, LIPC, CEL | HSD17B10 126/4885SMN1; SMN2 1723/4885ALDH1A1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.